BN Agrochem Limited Overview
BN Agrochem Limited is a re-activated listed shell turned edible-oil and agri-commodity trading platform. For most of its life as Arihant Tournesol it was a small Solapur-based sunflower and soybean solvent-extraction and refining company marketing oil under the "Sunari" brand; operations ceased and the stock became dormant, at one point suspended for listing non-compliance. In December 2022 the company was acquired by Anubhav Agarwal of the Noida-based BN Group, renamed BN Holdings and then BN Agrochem, recapitalised through a USD 40 million FCCB programme listed in Mauritius, and given overseas trading subsidiaries in Singapore and London. Revenue rose from nil in FY2023 to ₹873 Cr in FY2026, largely from offshore edible-oil and agri-product trading at thin margins. The investment case now hinges on a pending three-way amalgamation with BN Group's operating companies (A1 Agri Global, B.N. Agritech, Salasar Balaji Overseas), which would convert it into the group's consolidated listed edible-oil vehicle.
Company's own description (Annual Reports FY2022-23 and FY2023-24): The company describes itself as engaged in acquiring interests in companies that deal in manufacturing and trading various kinds of oil, oil seeds, solvent extraction, extracted oil cakes and refined oil. The FY2022-23 report states it was recently acquired by Mr. Anubhav Agarwal, promoter and director and key personnel of the BN Group. The FY2023-24 report, as summarised by Screener, adds an aspiration to go international as a Food and FMCG company and to expand into renewable energy. The FY2024-25 report states the company continues to focus on the edible oils and agri-products trading segment. Data vendors (Kotak Neo) further note that the objects have been broadened to include solar and wind energy systems, software development, system integration and IT-enabled services.
Independent characterisation: In substance, BN Agrochem today is a commodity trading business, not a manufacturer. The evidence:
-
Fixed assets were approximately ₹1 Cr at 31 March 2026 against revenue of ₹873 Cr (consolidated), an asset intensity inconsistent with crushing or refining capacity.
-
Operating (EBITDA) margins were 2.5% in FY2025 and 2.6% in FY2026 (Screener, consolidated) — typical of merchant trading of edible oils, not of branded FMCG.
-
Screener's AI-extracted insights flag a top-customer concentration metric naming KLB International, indicating material dependence on a small number of counterparties (percentage not publicly visible).
Business model / revenue model mix:
Value-chain position: Mid-stream merchant/trader between origin suppliers (palm, soybean, sunflower oil and oilseeds) and industrial buyers, refiners and distributors. Post-amalgamation, the company would absorb B.N. Agritech and related entities, which—based on group disclosures—are involved in edible-oil processing and distribution in India, moving it upstream into processing and downstream into branded distribution (the precise asset base of the transferor companies is not publicly disclosed in sources reviewed).
Customer types: Business-to-business buyers of edible oil and agri-commodities (named counterparty: KLB International, per Screener insight tag). Retail consumers were served only historically under the "Sunari" brand.
End-markets: Indian and international edible oil markets (palm, soybean, sunflower, mustard), oilseed meal (de-oiled cake) for animal feed, and—per BN Group's stated plans—African edible oil and soap markets.
Strategy
Stated strategic themes (Annual Reports FY2022-23 to FY2024-25, company website, Screener key points):
-
Build an internationally recognised edible-oils and FMCG company — the stated rationale for the 2022 acquisition by the BN Group promoter.
-
International expansion via overseas subsidiaries — Singapore (palm oil wholesale hub) and London.
-
Consolidate BN Group's operating businesses into the listed entity — the Scheme of Amalgamation, justified by operational synergies, centralised procurement and improved cash-flow management (NCLT coverage, ScanX).
-
Diversify into a conglomerate — renewable energy (solar, wind) and technology services (software, system integration, ITeS) added to objects.
-
Access international capital — USD 10 million foreign investment consideration (Apr 2023), followed by the USD 40 million FCCB programme on AFRINEX.
Initiative register (last 24 months):
ESG commitments / cost programmes: None publicly disclosed.
Medium-term financial targets / guidance: None publicly disclosed. The company does not issue guidance.
Products & Services
The company does not publish a product catalogue, price list or SKU data. The table records every product category referenced in public filings.
Flagship offerings: None currently named. No product launches, specifications or version years are publicly disclosed for the post-2022 business.
Product Portfolio
| Product / brand | Segment | Description | Target customer | Period | Pricing model |
|---|---|---|---|---|---|
"Sunari" edible oil (legacy brand) | Edible oils | Branded edible cooking oil (sunflower/soy) produced at Solapur refinery | Retail and wholesale consumers in Maharashtra | 1990s – mid-2000s; currently not disclosed as active | — |
Crude & refined edible oils (palm, soybean, sunflower, etc.) | Trading | Bulk merchant trading of edible oils | Refiners, packers, industrial buyers, international counterparties (e.g., KLB International) | FY2024 – present | Commodity-linked, spot/contract (terms not disclosed) |
Oil seeds | Trading | Trading of oilseeds | Crushers, processors | FY2024 – present | Commodity-linked |
Extracted oil cakes / de-oiled cake (DOC) | Trading / legacy manufacturing | Protein meal from solvent extraction; feed input | Feed manufacturers, exporters (historic soybean meal order from Germany) | Historic; mentioned in current object description | Commodity-linked |
Solvent extraction services | Legacy | Extraction of oil from seeds/cakes | — | 1995 – mid-2000s | — |
Other agricultural produce | Trading | General agri-produce trading | B2B | FY2024 – present | — |
Soaps and palm by-products (planned, BN Group) | Africa expansion | Palm-oil-based by-products announced by BN Group | African retail via direct-to-store, later distributors | Announced Dec 2024; operations expected Q4 FY2027 | — |
Renewable energy (solar, wind systems) | New objects | Object-clause expansion | — | Not operational per filings | — |
Software, system integration, ITeS | New objects | Object-clause expansion | — | Not operational per filings | — |
“—” = not publicly disclosed.
Financial Narrative
Data basis: FY2022 figures are standalone (no subsidiaries existed). FY2023–FY2026 are consolidated (Screener / company results). Blank cells = not publicly disclosed or not available in sources reviewed.
Income Statement
Sources: Screener consolidated and standalone P&L; FY2025/FY2026 net profit ₹1,975.56 lakh and ₹3,436.72 lakh per company results (5paisa summary). Gross profit not disclosed (cost of goods sold not separately available in sources reviewed). Diluted EPS not separately disclosed; given FCCB conversions in FY2025, basic and diluted may differ materially for FY2025 (weighted share count rose from ~0.99 Cr to 9.78 Cr shares).
Note on EPS discontinuity: FY2024 EPS of -₹3.16 is on ~0.99 crore shares; FY2025 onwards EPS is on ~9.78 crore shares post-FCCB conversion. Per-share comparisons across FY2024/FY2025 are not like-for-like.
Margins & Growth
Analyst calculations. Revenue CAGR FY2024–FY2026 (2 years) ≈ 1,010% (from ₹7.09 Cr to ₹873.28 Cr); a 5-year CAGR is not meaningful because the FY2022 and FY2023 bases are zero.
Quarterly Trajectory (Consolidated)
Source: Screener consolidated quarterly results. Minor vendor differences: Q4FY26 revenue reported as ₹261.36 Cr (Screener), ₹261.72 Cr (Kotak Neo) and ₹261.36 Cr (company: ₹26,135.66 lakh); Q1FY27 revenue ₹257.51 Cr (Screener/Business Standard) vs ₹257.61 Cr (ScanX, company: ₹25,760.75 lakh).
Commentary — income statement: The business has three distinct phases. (i) FY2022–FY2024: a dormant shell with sub-crore expenses and no revenue, ending with a first ₹7.09 Cr trading quarter in Q4FY24 under the new promoter. (ii) FY2025: the ramp-up year, in which trading started in earnest only from Q3FY25 (after the Singapore and London subsidiaries were capitalised by FCCB proceeds). Reported profitability that year was flattered by other income: Q4FY25 recorded an operating loss of ₹40.55 Cr offset by ₹61.44 Cr of other income — the nature of which (FX gains on FCCB liabilities, fair-value gains, or reclassified trading income) is not disclosed in sources reviewed and is a key diligence item. (iii) FY2026: revenue nearly tripled to ₹873 Cr, but quarterly operating margins oscillated violently (11.7% in Q1, 0.6% in Q2, -8.4% in Q3, 1.6% in Q4), consistent with mark-to-market exposure on commodity positions or lumpy deal-level margins. Critically, FY2026 net profit (₹34.4 Cr) exceeded PBT (₹20 Cr) because of a large tax credit (tax rate -74%), concentrated in Q2FY26 when net profit of ₹17.92 Cr was booked on PBT of just ₹0.57 Cr. Stripping that out, FY2026 "core" earnings were materially lower than headline. Q1FY27 continued the low-margin pattern: revenue +27% YoY to ₹257.6 Cr, net profit -85% YoY to ₹2.98 Cr as EBITDA margin contracted from 11.71% to 2.29% (ScanX).
Standalone vs Consolidated
Source: company results as summarised by 5paisa (standalone FY2025 revenue ₹2,562.89 lakh; standalone FY2025 net loss ₹5,963.13 lakh; FY2026 standalone revenue ₹23,262.30 lakh and net profit ₹1,934.95 lakh). The FY2025 standalone loss of ~₹59.6 Cr alongside a consolidated profit implies large standalone charges (possibly FCCB discount amortisation/FX losses or impairments) offset by subsidiary profits.
Balance Sheet (Consolidated)
Source: Screener consolidated balance sheet; FY2022 paid-up capital ₹9.90 Cr per MCA registry (₹9,89,83,000). Short-/long-term split of borrowings, cash balance, goodwill and working-capital line items not publicly disclosed in sources reviewed. Book value per share ₹47.7 (Screener) reconciles to ₹467 Cr / 9.78 Cr shares.
Observations: The ₹72 Cr investment line that appeared in FY2024 and stayed flat through FY2026 is notable; in a consolidated balance sheet, investments in wholly owned subsidiaries would be eliminated, so this likely represents a non-consolidated investment (nature not publicly disclosed). The ₹294 Cr jump in reserves in FY2025 reflects securities premium from FCCB conversion (₹88 Cr face value of new shares plus premium), not retained earnings. Borrowings of ₹83 Cr at FY2025 (likely including unconverted FCCB liability) fell to ₹51 Cr in FY2026.
Cash Flow (Consolidated)
Source: Screener consolidated cash flow. FY2022 cash flow not available on consolidated basis.
Commentary — cash flow: FY2025 financing inflow of ₹327 Cr (FCCB proceeds) was deployed as ₹282 Cr of investing outflow — the composition of which (loans/advances, inter-corporate deposits, investments) is not disclosed in sources reviewed. Given that fixed assets and the investment line barely moved, a large part of this "investing" outflow likely represents loans or advances, potentially to related parties; this should be verified against the FY2025 annual report cash-flow notes. FY2026 is the first year of positive operating cash flow (₹24 Cr; CFO/EBITDA 123%), with ₹26 Cr of investing inflow (recoveries) used to reduce financing by ₹43 Cr.
Ratios
Sources: ROCE, debtor days, CCC and working-capital days from Screener; ROE/ROA/D/E/coverage/asset turnover are analyst calculations on average balances (FY2024 ROE from Screener's -8.88%). Current ratio, ROIC and net debt/EBITDA cannot be computed because cash and current-asset/current-liability splits are not publicly disclosed in sources reviewed. Screener flags "low interest coverage" on a trailing-twelve-month basis (TTM EBITDA -₹5 Cr).
Commentary — ratios: The 352 debtor days at FY2025 indicate that most of FY2025's ₹299 Cr revenue (booked largely in Q3–Q4) was still receivable at year-end; their collapse to 59 days by FY2026 is a positive. However, working-capital days rising from 79 to 172 shows that capital is tied up elsewhere (advances, other current assets). Zero inventory days across years corroborates the back-to-back trading model. ROE of ~8% on a heavily premium-inflated equity base is low for a trading business and well below the 13.4% three-year average Screener computes (which is skewed by FY2025's ROCE spike).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Relationship | Jurisdiction | Function |
|---|---|---|---|
BN Agrochem Limited | Listed parent | India (Mumbai) | Edible oil / agri trading; holding company |
BN Holdings Singapore Pte. Limited | Subsidiary (incorporated as WOS 14 Feb 2024; listed as "Subsidiary" in FY2024-25 RPT note) | Singapore — OCBC Centre, 65 Chulia Street #42-07 | Registered activities: wholesale trade of variety of goods; wholesale of palm oil; manufacture of edible oils and fats |
BN Holdings Europe Limited | Wholly owned subsidiary (shares acquired 1 Jul 2024) | London, England | Overseas trading/expansion (detailed activities not publicly disclosed) |
B.N. Corporate Park Pvt Limited | Related company (lessor) | India | Lease rent paid by the company |
B.N. Agritech Limited | Promoter group company; proposed transferor; beneficiary of corporate guarantees | India | Edible-oil business with listed NCDs (MITCON Credentia as debenture trustee) |
A1 Agri Global Limited | Promoter group; proposed transferor | India | Agri trading (details not publicly disclosed) |
Salasar Balaji Overseas Private Limited | Promoter group; proposed transferor | India | Agri/overseas trading (details not publicly disclosed) |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Edible oils & agri trading revenue (INR Cr) | 7.09 | 299.41 | 873.28 |
Segment operating profit / EBITDA (INR Cr) | -3.09 | 7 | 22 |
Segment EBITDA margin (%) | -43.6 | 2.5 | 2.6 |
YoY revenue growth (%) | — | 4,123 | 192 |
Contribution to total revenue (%) | 100 | 100 | 100 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 0 | 0 | 7.09 | 299.41 | 873.28 |
Total expenses excl. interest & depreciation (INR Cr) | 0.17 | 0.20 | 10.18 | 292 | 851 |
EBITDA / Operating profit before other income (INR Cr) | -0.17 | -0.20 | -3.09 | 7 | 22 |
Other income (INR Cr) | — | -0.15 | 0 | 23 | 0 |
Interest expense (INR Cr) | — | 0.02 | 0.04 | 9 | 2 |
Depreciation (INR Cr) | — | 0 | 0 | 0 | 1 |
Profit before tax (INR Cr) | — | 0 | -3 | 22 | 20 |
Tax rate (%) | — | 0 | 0 | 9 | -74 |
Net profit (INR Cr) | — | -0.37 | -3 | 19.76 | 34.37 |
EPS basic (INR) | — | -0.37 | -3.16 | 2.02 | 3.52 |
Dividend per share (INR) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
EBITDA margin (%) | -43.6 | 2.5 | 2.6 |
PBT margin (%) | -42.3 | 7.3 | 2.3 |
Net margin (%) | -42.3 | 6.6 | 3.9 |
Revenue YoY growth (%) | — | 4,123 | 192 |
Income Statement and Margin Analysis (%) (Quarterly)
| Metric | Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (INR Cr) | 0 | 0 | 0 | 7.09 | 0 | 0 | 85.22 | 214.19 | 203.31 | 216.49 | 192.12 | 261.36 | 257.51 |
Operating profit (INR Cr) | -0.30 | -0.61 | -1.26 | -0.90 | -1.07 | -3.51 | 7.82 | -40.55 | 23.81 | 1.28 | -16.15 | 4.22 | 5.91 |
OPM (%) | — | — | — | -12.69 | — | — | 9.18 | -18.93 | 11.71 | 0.59 | -8.41 | 1.61 | 2.30 |
Other income (INR Cr) | -0.04 | 0 | 0 | 0 | 0.10 | 0 | 6.27 | 61.44 | 0.01 | 0 | 8.76 | 0.37 | 0.03 |
Interest (INR Cr) | 0 | 0 | 0 | 0.01 | 1.25 | 2.88 | 2.93 | 1.64 | 0.45 | 0.52 | 0.48 | 0.50 | 0.52 |
Profit before tax (INR Cr) | -0.34 | -0.61 | -1.26 | -0.91 | -2.23 | -6.41 | 11.14 | 19.17 | 23.18 | 0.57 | -8.06 | 3.89 | 5.21 |
Net profit (INR Cr) | -0.34 | -0.61 | -1.26 | -0.91 | -1.92 | -5.69 | 10.09 | 19.25 | 20.08 | 17.92 | -6.78 | 2.95 | 2.98 |
Income Statement
| Metric | FY2025 | FY2026 |
|---|---|---|
Standalone revenue (INR Cr) | 25.63 | 232.62 |
Consolidated revenue (INR Cr) | 299.41 | 873.28 |
Standalone net profit (INR Cr) | -59.63 | 19.35 |
Consolidated net profit (INR Cr) | 19.76 | 34.37 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Equity share capital (INR Cr) | 9.90 | 10 | 10 | 98 | 98 |
Reserves (INR Cr) | — | -10 | 61 | 294 | 369 |
Total equity / net worth (INR Cr) | — | 0 | 71 | 392 | 467 |
Borrowings — total (INR Cr) | — | 1 | 1 | 83 | 51 |
Other liabilities (INR Cr) | — | 0 | 0 | 188 | 8 |
Total assets (INR Cr) | — | 0 | 72 | 662 | 526 |
Fixed assets (INR Cr) | — | 0 | 0 | 1 | 1 |
Investments (INR Cr) | — | 0 | 72 | 72 | 72 |
Other assets incl. receivables & cash (INR Cr) | — | 0 | 0 | 589 | 453 |
Cash Flow
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Cash from operating activities (INR Cr) | 0 | -3 | -38 | 24 |
Cash from investing activities (INR Cr) | 0 | -72 | -282 | 26 |
Cash from financing activities (INR Cr) | 0 | 75 | 327 | -43 |
Net cash flow (INR Cr) | 0 | 0 | 6 | 7 |
Capex (INR Cr) | 0 | 0 | 1 | 0 |
Free cash flow (INR Cr) | 0 | -3 | -39 | 24 |
Dividends paid (INR Cr) | 0 | 0 | 0 | 0 |
Buybacks (INR Cr) | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
ROE (%) | -8.9 | 8.5 | 8.0 |
ROA (%) | -8.3 | 5.4 | 5.8 |
ROCE (%) | -9 | 27 | 4 |
Debt / equity (x) | 0.01 | 0.21 | 0.11 |
Interest coverage, EBIT/interest (x) | — | 3.4 | 11.0 |
Asset turnover (x) | 0.20 | 0.82 | 1.47 |
Debtor days | 0 | 352 | 59 |
Inventory days | 0 | 0 | 0 |
Cash conversion cycle (days) | 0 | 352 | 59 |
Working capital days | -3 | 79 | 172 |
Revenue by Region and Revenue by Region (%)
| Region (derived) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
India — standalone entity revenue (INR Cr) | 7.09 | 25.63 | 232.62 |
Overseas subsidiaries — consolidated less standalone (INR Cr) | 0 | 273.78 | 640.66 |
Total consolidated revenue (INR Cr) | 7.09 | 299.41 | 873.28 |
Overseas share of total (%) | 0 | 91.4 | 73.4 |
India share of total (%) | 100 | 8.6 | 26.6 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Price (19 Oct 2026 close) | ₹159 | Screener |
52-week high / low | ₹420 / ₹158 | Screener |
1-year return | -60% | Screener |
3-year CAGR | 39% | Screener |
5-year CAGR | 96% | Screener |
Shareholders (Sep 2026) | 9,422 | Screener |
Share Price and Market Valuation
| Metric | Pre-FCCB 2024 | Sep-2025 | Nov-2025 | Oct-2026 |
|---|---|---|---|---|
Share price (INR) | 158 | 368 | 366 | 159 |
Market cap (INR Cr) | 156 | 3,597 | 3,579 | 1,535 |
Valuation Multiples
| Multiple | BN Agrochem | Basis |
|---|---|---|
P/E (TTM) | 89.9× | Screener (TTM EPS ₹1.74) |
P/E (FY2026) | 45.2× | Analyst: ₹159 / ₹3.52 |
P/B | 3.33× | Screener (BV ₹47.7) |
EV/Sales (TTM) | ~1.7× | Analyst: (₹1,535 + ₹51 debt) / ₹927 Cr TTM revenue; gross of undisclosed cash |
EV/EBITDA (FY2026) | ~72× | Analyst: ~₹1,586 Cr / ₹22 Cr |
Dividend yield | 0.00% | Screener |
Peer P/E (GAEL / RBS) | 18.8× / 18.6× | Fyers |
Capital Markets
| Item | Status |
|---|---|
Dividend history | No dividends in any year reviewed (FY2013–FY2026); board cited conservation of resources (FY2021 AR) |
Credit ratings (Moody's / S&P / Fitch) | Not rated by international agencies; domestic ratings not publicly disclosed in sources reviewed |
Analyst consensus | No sell-side coverage identified |
Debt maturity | FCCBs originally due May 2029 (largely converted); remaining borrowings ₹51 Cr at FY2026, maturity profile not disclosed |
Analyst Conclusions
Management guidance: None issued. Consensus expectations: None (no coverage).
Bull case
-
Amalgamation transforms the asset base. Absorbing B.N. Agritech (₹92.68 Cr issued capital, listed NCDs), A1 Agri Global and Salasar Balaji would turn an asset-light trader into an integrated edible-oil group, potentially lifting margins above the current 2–3%.
-
Demonstrated ability to scale and convert to cash. Revenue went from ₹7 Cr to ₹873 Cr in two years, and FY2026 delivered positive operating cash flow (₹24 Cr) with receivable days down to 59.
-
Optionality from Africa and Singapore. If the listed company becomes the vehicle for BN Group's USD 1 bn Africa programme, the growth runway is large relative to a ₹1,535 Cr market cap.
Bear case
-
Earnings quality is weak. FY2026 net profit relied on a large tax credit; FY2025 relied on other income; TTM EBITDA is negative, leaving the stock on ~90× trailing earnings versus peers near 19×.
-
Governance and related-party risk. 89.88% of equity is held by unnamed foreign companies from FCCB conversions, the promoter holds 5.93% directly but controls the transferor companies, and the listed entity is extending guarantees (₹25 Cr cumulative) to a promoter-group company.
-
Dilution and value transfer. On analyst assumptions, the scheme could issue ~18.4 Cr new shares (~65% of the enlarged equity) to holders of promoter-group companies whose standalone financials are not publicly disclosed in sources reviewed; minority shareholders bear valuation risk.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | What to watch |
|---|---|---|
| EGM on ₹10 Cr guarantee | 22 Oct 2026 | Vote outcome; minority dissent |
| NCLT-convened shareholder & creditor meetings | Within extended window (~Nov 2026) | Approval margins, especially of public (non-promoter) shareholders |
| Final NCLT sanction of scheme | FY2027 H2 (estimated) | Effective date; final share count |
| Q2FY27 results | ~Nov 2026 | Margin recovery; tax rate normalisation; other income |
| FY2026 annual report notes | Available on BSE | Composition of ₹282 Cr FY2025 investing outflow; ₹72 Cr investment; related-party balances |
| Identity of foreign shareholders | Ongoing | Any lock-in, sell-down or acting-in-concert disclosures |
| BN Group Africa operations | Targeted Q4 FY2027 | Whether listed entity participates |
| Exchange surveillance | Ongoing | ASM/GSM framework inclusion, further clarifications |
Analyst verdict
BN Agrochem is best understood not as an edible-oil company in the conventional sense but as a listed vehicle in the middle of a promoter-led corporate reconstruction. The original Arihant Tournesol — a 1990s Solapur sunflower and soybean processor — no longer exists in any operational sense; what remains is a listing, a ₹10 face-value share structure and a new owner's ambition. Since December 2022 the BN Group has used that listing effectively: it raised USD 40 million through Mauritius-listed FCCBs, converted them into equity, set up trading arms in Singapore and London, and scaled revenue to ₹873 Cr in FY2026.
The quality of what has been built, however, remains unproven. Margins are commodity-trader thin and highly erratic; reported profits in each of the last two years leaned on non-operating items (other income in FY2025, tax credits in FY2026); trailing EBITDA is negative; and the largest use of FCCB money appears in investing cash flows whose nature is not transparently disclosed. Ownership is unusual — nearly nine-tenths of the equity sits with unnamed foreign companies — and the listed entity is already guaranteeing borrowings of a promoter-group company it intends to absorb.
The pending amalgamation is therefore the decisive event. If the transferor companies bring genuine processing and distribution assets with sound earnings, the merged entity could justify a premium to today's trading business. If not, minority shareholders face heavy dilution into opaque private businesses at a valuation that already prices in considerable success (≈90× trailing earnings, 3.3× book, versus integrated peers near 19× earnings).
On balance, the evidence supports a cautious, diligence-first stance. The stock's 60% decline over the past year reflects a market already discounting these risks, but until the transferor companies' financials, the identity of the foreign shareholders and the FY2025 cash deployment are clarified, BN Agrochem remains a high-risk special situation rather than an investable edible-oil franchise.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Since | Prior roles / profile | Education | Age |
|---|---|---|---|---|---|
Anubhav Agarwal | Promoter; Non-Executive Director (described as Non-Executive Chairman by Investing.com) | Board 30 Dec 2022; MD & CEO until 21 May 2025 | Founder & MD of BN Group (edible oils, Noida); redesignated to non-executive to pursue business outside India | MBA (per FY2024-25 AR profile) | 37–38 (vendor data) |
Chintan Ajaykumar Shah | Whole-Time Director & CEO | 21 May 2025 | — | — | — |
Manisha Kumari | Chief Financial Officer | 2 Feb 2023 | — | — | — |
Rakesh Kumar Verma | Independent Non-Executive Director | 27 Feb 2023 | — | — | — |
Shalu Saraf | Independent Non-Executive Director | 27 Feb 2023 | — | — | — |
Rakesh Kumar | Independent Non-Executive Director | 12 Aug 2024 (additional) | — | — | 65 |
Sandeep Chauhan | Additional Non-Executive Independent Director | 2025 | — | — | — |
Company Secretary | — | — | Reetika Mahendra signed the FY2023-24 AR filing (31 Aug 2024); current CS not confirmed | — | — |
“—” = not publicly disclosed.
Board of Directors — Varsha Sethi
| Name | Role | Period |
|---|---|---|
Varsha Sethi | Chairman | c. 2013 |
Ajit Kumar Kasturchand (A.K.) Sethi | Director | 2000s–2010s |
Rajivkumar Sethi | Non-Executive Director | 2018–2022 |
Dayanand Jagdish (D.N.) Jha | Director | 1999–2022 |
K. Ramkrishnan | Director | c. 2013 |
Kalpita Laxman Sawant | Additional Director | 2011–2010s |
Rajendra (Rajender Lilaram) Gurnani | Director | c. 2013 |
Karthyayani Narayanan Kutty | Director | 2017–2022 |
Governance Overview
| Attribute | Status |
|---|---|
Board size | ~6 (1 executive, 1 non-executive promoter, 4 independent including additional director) |
Independence | Majority independent on latest composition |
Chair/CEO separation | Yes since May 2025 (Agarwal non-executive; Shah CEO) |
Committees | Audit, Nomination & Remuneration, Stakeholders' Relationship (statutory); Agarwal listed as member of a committee in FY2024-25 AR; full composition not publicly disclosed in sources reviewed |
Women directors | Shalu Saraf (1) |
Compliance history | BSE "SOP fine" communication received July 2024 (Regulation 30 disclosure); historic suspension for listing non-compliance |
Shareholding Trend
| Holder category | Mar-2024 (%) | Dec-2024 (%) | Mar-2025 (%) | Sep-2026 (%) |
|---|---|---|---|---|
Promoters | 58.60 | 55.23 | 5.93 | 5.93 |
FIIs | 0.00 | 0.22 | 0.02 | 0.00 |
Public (incl. foreign companies) | 41.40 | 44.54 | 94.04 | 94.07 |
No. of shareholders | 8,968 | 9,056 | 9,070 | 9,422 |
Major Shareholders
| Holder | Shares | % |
|---|---|---|
Foreign companies (FCCB conversion allottees) | 87,874,641 | 89.88 |
Anubhav Agarwal (promoter) | 5,800,000 | 5.93 |
Resident individuals | 3,437,499 | 3.52 |
Body corporates | 438,262 | 0.45 |
Non-resident individuals | 166,274 | 0.17 |
Other shareholders | 32,439 | 0.03 |
Foreign portfolio investors | 23,626 | 0.02 |
Domestic institutions | 200 | 0.00 |
Total | 97,772,941 | 100.00 |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Scale / data point | Positioning vs BN Agrochem |
|---|---|---|---|
AWL Agri Business (formerly Adani Wilmar) | Edible oil refining, brands (Fortune), import trading | — | Vastly larger, integrated, branded |
Patanjali Foods (formerly Ruchi Soya) | Edible oil processing, solvent extraction, brands | — | Integrated soybean/palm processor; similar solvent-extraction heritage |
Gujarat Ambuja Exports (GAEL) | Agro-processing, solvent extraction, maize/soy | Market cap ₹7,825 Cr, P/E 18.8, annual PAT ₹304 Cr (Fyers peer table) | Profitable integrated processor; 9× BN Agrochem PAT |
Gokul Agro Resources | Edible oil import, refining, trading | — | Closest listed model to an import-led trader-refiner |
Cargill India | Edible oil refining & trading | Unlisted; not disclosed | Global trading major |
Wilmar International / Olam (global) | Palm oil origination & trading (Singapore hubs) | — | Direct competitors to the Singapore subsidiary |
Emami Agrotech | Edible oil refining | Unlisted/subsidiary; not disclosed | Regional brand competitor |
Vijay Solvex | Solvent extraction & refining (Rajasthan) | — | Small-cap processor peer |
Kriti Nutrients | Soybean solvent extraction | — | Small-cap processor peer |
Bidco Africa / Murzah Wilmar | African edible oil and soaps | — | Incumbents in BN Group's targeted African markets |
RBS (SME listing) | Trading (Fyers peer set) | Price ₹88.5, m-cap ₹212 Cr, P/E 18.6, PAT ₹11 Cr | Small trading peer |
Shanti (Fyers peer set) | Trading | M-cap ₹7 Cr, loss-making | Micro peer |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | BN Agrochem | Gujarat Ambuja Exports | RBS (SME) |
|---|---|---|---|
Market cap | 1,535 | 7,825 | 212 |
Annual PAT | 34 | 304 | 11 |
P/E (x) | 89.9 | 18.8 | 18.6 |
EV/EBITDA (x, Fyers) | 1.83 (vendor figure; see note) | 12.03 | 6.98 |



